Arecor Therapeutics PLC Progress of Phase I clinical study of AT278 (2656O)
02 10월 2023 - 3:00PM
UK Regulatory
TIDMAREC
RNS Number : 2656O
Arecor Therapeutics PLC
02 October 2023
Arecor Therapeutics plc
("Arecor" or the "Group")
Arecor provides update on progress of second Phase I clinical
study of ultra-rapid, ultra-concentrated insulin candidate
AT278
Cambridge, UK, 2 October 2023: Arecor Therapeutics plc (AIM:
AREC), the biopharmaceutical group advancing today's therapies to
enable healthier lives, today announces that, in line with the
update provided within its Interim Results on 14 September, the
Group has taken the decision to increase the number of subjects
within its ongoing Phase I clinical trial of ultra-rapid,
ultra-concentrated insulin candidate AT278.
The increase in the number of subjects within the study, from 32
to 42, will increase the power of the study and, in turn, increase
the value of the results for patients with high insulin needs.
Results are expected in early 2024.
Sarah Howell, Chief Executive Officer at Arecor, said: " Having
already demonstrated AT278's very promising profile in Type 1
diabetic patients, this is a key clinical study for AT278 in the
Type 2 patient population. The number of people living with Type 2
diabetes is increasing, year-on-year, driven by the obesity
epidemic, and many patients are becoming insulin resistant,
requiring large volumes of insulin and multiple injections to
manage their condition, which is a heavy daily burden. AT278 has
the potential to be the first, and potentially only, highly
concentrated and very rapid acting insulin and thereby become the
gold standard insulin for those with high daily insulin needs.
AT278 also has the potential to be a critical enabler in the
development of next generation miniaturised and longer wear insulin
delivery systems. And with all three major insulin device companies
having access to patch pump technology, we expect an acceleration
in the development of these next generation systems, which require
a concentrated rapid acting insulin."
The trial is a double blind, randomised, crossover study
comparing the pharmacokinetic (PK) and pharmacodynamic (PD) profile
following a single subcutaneous dose of 0.5 U/Kg of AT278 (500
U/mL) with NovoRapid(R) (100 U/mL) in 42 people with Type 2
diabetes in a euglycemic clamp setting. In addition, the PK/PD
profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R
U500(R) will be evaluated in each of the participants.
-ENDS-
For more information, please contact:
Arecor Therapeutics plc www.arecor.com
Dr Sarah Howell, Chief Executive Tel: +44 (0) 1223 426060
Officer Email: info@arecor.com
Susan Lowther, Chief Financial Officer Tel: +44 (0) 1223 426060
Email: info@arecor.com
Mo Noonan, Communications Tel: +44 (0) 7876 444977
Email: mo.noonan@arecor.com
Panmure Gordon (UK) Limited (NOMAD
and Broker)
Freddy Crossley, Emma Earl (Corporate Tel: +44 (0) 20 7886 2500
Finance)
Rupert Dearden (Corporate Broking)
ICR Consilium
Chris Gardner, David Daley, Lindsey Tel: +44 (0) 20 3709 5700
Neville Email: arecor@consilium-comms.com
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical
group transforming patient care by bringing innovative medicines to
market through the enhancement of existing therapeutic products. By
applying our innovative proprietary formulation technology
platform, Arestat(TM) , we are developing an internal portfolio of
proprietary products in diabetes and other indications, as well as
working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The
Arestat (TM) platform is supported by an extensive patent portfolio
. For further details please see our website, www.arecor.com
-
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFSSFUFEDSESS
(END) Dow Jones Newswires
October 02, 2023 02:00 ET (06:00 GMT)
Arecor Therapeutics (LSE:AREC)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Arecor Therapeutics (LSE:AREC)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024